Study of Inhaled Glucocorticosteroid Administration in Asthma Patients

Completed

• Conditions: Asthma
• Interventions: Drug: Budesonide,hydrofluoroalkane-beclomethasone; Drug: Budesonide,hydrofluoroalkane-beclomethasone dipropionate

• Registration Number: NCT00559689
• Lead Sponsor: Hamamatsu University

Brief Summary

Once-daily inhaled glucocorticosteroids treatment can sufficiently control airway inflammation in asthma patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-11
• Study Completion: 2007-03
• Study First Submitted: 2007-11-15
• Study First Submitted QC: 2007-11-15
• Study First Posted: 2007-11-16
• Status Verified: 2009-03
• Last Update Submitted: 2009-03-13
• Last Update Posted: 2009-03-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

• Receive ICS for one year or more, with no change in dose within the previous 8 weeks

Exclusion Criteria

• Two or more courses of oral corticosteroid in the previous 12 months
• Admission to hospital due to asthma in the previous 6 months
• Admission to the intensive care unit due to asthma at any time in the past
• Current cigarette smoker.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
1	Budesonide,hydrofluoroalkane-beclomethasone	receive once-daily administration of inhaled glucocorticosteroids at bedtime
2	Budesonide,hydrofluoroalkane-beclomethasone dipropionate	receive twice-daily administration of inhaled glucocorticosteroids

Primary Outcome Measures

Name	Time	Method
once-daily administration of inhaled glucocorticosteroids can control airway inflammation	two-year

Trial Locations

Locations (1)

Hamamatsu University School of Medicine; 🇯🇵 Hamamatsu, Japan